Insmed Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: -244.21%

Insmed Incorporated EBITDA Margin is -244.21% for the Trailing 12 Months (TTM) ending March 31, 2025, a 18.42% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Insmed Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -206.21%, a 8.58% change year over year.
  • Insmed Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -189.92%, a 0.79% change year over year.
  • Insmed Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -188.43%, a 15.35% change year over year.
  • Insmed Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -163.35%, a 19.77% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin